Analysts’ Viewpoint on Premenstrual Syndrome Treatment Market Scenario
Pharmaceutical companies are increasing their production capacities of antidepressants, hormonal contraceptives, and nonsteroidal anti-inflammatory drugs (NSAIDs) to avoid supply shocks in pharmacies. Healthcare companies are currently scaling growth opportunities in mobile apps, which help provide psychological support to women. The trend of telemedicine is gaining traction. The COVID-19 pandemic had a marginal negative impact on the premenstrual syndrome treatment market. Manufacturers in the market were adopting agile supply node networks to adapt to volatility in demand and supply. An increasing number of individuals were avoiding trips outside of the house to limit their exposure to COVID-19. Therefore, manufacturers have diversified their supply chains via e-commerce to broaden their revenue streams.
Premenstrual syndrome, or PMS, is the term used to describe a group of physical and psychological symptoms that develop one to two weeks prior to the start of a woman's menstrual cycle. These symptoms include acne, sore breasts, mood swings, bloating, exhaustion, and irritability. The market is growing as a result of factors such as increased public knowledge of premenstrual syndrome symptoms and treatments, a larger target market, rising PMS drug demand, and accessibility of medications. A majority of women who have PMS are typically in their 30s.
Women are susceptible to adverse events caused due to the administration of antidepressants, diuretics, and nonsteroidal anti-inflammatories. Thus, manufacturers operating in the premenstrual syndrome treatment or dysmenorrhea treatment market are focusing on vitamin supplements and herbal medicines to ease premenstrual syndrome (PMS) in women. Supplements made from micronutrients such as calcium, magnesium, vitamin B6, and potassium are being highly publicized for the effective management of premenstrual syndrome. However, many supplements are not regulated by the FDA (Food & Drug Administration) and could interfere with prescription medications. Hence, companies in the premenstrual syndrome treatment market are educating women to seek a doctor’s consultation to avoid risks of the side-effects. Mood-boosting supplements induced with vitamin B6 are in high demand. Organic chasteberry in nutritional supplements is gaining popularity for easing anxiety and depression.
Almost three in four women experience premenstrual syndrome at some point in their lives. According to a study that was published in the General Psychiatry Journal 2020, 90% of women of reproductive age were likely to experience various premenstrual symptoms, ranging in severity from mild to severe. Around 20% to 40% of women experience premenstrual syndrome. Rising incidence of premenstrual dysphoric disorder (PMDD) in different parts of the world is one of the primary factors fueling the premenstrual syndrome treatment market size. Sedentary lifestyles and demanding schedules of the female working population could be blamed for this. Furthermore, growing awareness among the general public regarding luteal phase therapy or different treatment options for PMS and other related disorders is also driving the market. Pharmaceutical companies are releasing drugs that help the body's pH level stay balanced while having few side-effects. Premenstrual syndrome treatment is gaining popularity, which in turn is boosting the market
Use of antidepressants, diuretics, and nonsteroidal anti-inflammatory drugs could have negative side-effects on women. Manufacturers operating in the premenstrual syndrome treatment market are concentrating on vitamin supplements and herbal medications to help women with premenstrual syndrome (PMS). Furthermore, acupuncture-related products are gaining traction for treating pain.
It is widely known that taking supplements containing micronutrients such as calcium, magnesium, vitamin B6, and potassium could effectively treat premenstrual syndrome. The FDA (Food & Drug Administration) does not regulate various supplements; however, they could conflict with prescription drugs. Businesses in the premenstrual syndrome treatment market are educating women to consult a doctor in order to reduce the risk of side-effects. Vitamin B6-based supplements that improve mood are in high demand. Organic chaste berry nutritional supplements are rising in popularity for reducing anxiety and depression.
In terms of drug type, the global premenstrual syndrome treatment market has been split into antidepressants, diuretics, pain relievers, oral contraceptives & ovarian suppression agents, and others. Combined oral contraceptives may reduce overall premenstrual symptomatology in women with premenstrual syndrome or premenstrual dysphoric disorder. Therefore, the oral contraceptives & ovarian suppression drugs segment held a majority of the premenstrual syndrome treatment market share.
North America accounted for a significant share of the global premenstrual syndrome treatment in 2021. According to an article published by National Library of Medicine, in the U.S., approximately 70% to 90% of women in the reproductive age group reported at least some premenstrual discomfort. Approximately one-third of these women have symptoms that are bothersome enough to qualify for the diagnosis of PMS. The most severe form of premenstrual symptom complex, PMDD, has been noted in 3% to 8% of these PMS cases. The market in Asia Pacific is estimated to rise at a notable CAGR during the forecast period due to increasing awareness regarding premenstrual syndrome treatment in the region.
The report concludes with the company profiles section, which includes information about key players in the global premenstrual syndrome treatment market. Expansion of product portfolio and mergers & acquisitions are prominent strategies adopted by key players in the market. Allergan (AbbVie, Inc.), Bayer AG, Fresenius Kabi AG, Johnson & Johnson Services, Inc., Lilly, Mylan N.V. (Viatris Inc.), Pfizer, Inc., and Teva Pharmaceutical Industries Ltd. are prominent players in the global premenstrual syndrome treatment market.
Each of the key players has been profiled in the premenstrual syndrome treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 1.3 Bn |
|
Market Forecast Value in 2031 |
More than US$ 1.9 Bn |
|
Growth Rate (CAGR) for 2022-2031 |
3.4% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, the qualitative analysis includes market drivers, restraints, opportunities, key trends, and a parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global premenstrual syndrome treatment market was valued at US$ 1.3 Bn in 2021.
The global premenstrual syndrome treatment market is projected to reach more than US$ 1.9 Bn by 2031.
The global premenstrual syndrome treatment market grew at a CAGR of 2.8% from 2017 to 2021.
The global premenstrual syndrome treatment market is anticipated to grow at a CAGR of 3.4% from 2022 to 2031.
The oral contraceptives & ovarian suppression agents segment held over 35% share of the global premenstrual syndrome treatment market in 2021.
North America is expected to account for the major share of the global premenstrual syndrome treatment market during the forecast period.
Allergan (AbbVie, Inc.), Bayer AG, Fresenius Kabi AG, Johnson & Johnson, Lilly, Mylan N.V. (Viatris Inc.), Pfizer, Inc., and Teva Pharmaceutical Industries Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Premenstrual Syndrome Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Premenstrual Syndrome Treatment Market Analysis and Forecast, 2017 - 2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence North America & Europe with Key Countries
5.3. Key Industry Events
5.4. COVID-19 Pandemic Impact on Industry
6. Global Premenstrual Syndrome Treatment Market Analysis and Forecast, by Drug Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Drug Type, 2017 - 2031
6.3.1. Antidepressants
6.3.2. Diuretics
6.3.3. Pain Relievers
6.3.4. Oral Contraceptives & Ovarian Suppression Agents
6.3.5. Others
6.4. Market Attractiveness, by Drug Type
7. Global Premenstrual Syndrome Treatment Market Analysis and Forecast, by Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
7.3.1. Retail Pharmacies
7.3.2. E-commerce
7.3.3. Others
7.4. Market Attractiveness, by Distribution Channel
8. Global Premenstrual Syndrome Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Premenstrual Syndrome Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Drug Type, 2017 - 2031
9.2.1. Antidepressants
9.2.2. Diuretics
9.2.3. Pain Relievers
9.2.4. Oral Contraceptives & Ovarian Suppression Agents
9.2.5. Others
9.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
9.3.1. Retail Pharmacies
9.3.2. E-commerce
9.3.3. Others
9.4. Market Value Forecast, by Country, 2017 - 2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Type
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Premenstrual Syndrome Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Drug Type, 2017 - 2031
10.2.1. Antidepressants
10.2.2. Diuretics
10.2.3. Pain Relievers
10.2.4. Oral Contraceptives & Ovarian Suppression Agents
10.2.5. Others
10.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
10.3.1. Retail Pharmacies
10.3.2. E-commerce
10.3.3. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017 - 2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Premenstrual Syndrome Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Drug Type, 2017 - 2031
11.2.1. Antidepressants
11.2.2. Diuretics
11.2.3. Pain Relievers
11.2.4. Oral Contraceptives & Ovarian Suppression Agents
11.2.5. Others
11.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
11.3.1. Retail Pharmacies
11.3.2. E-commerce
11.3.3. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017 - 2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Premenstrual Syndrome Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Drug Type, 2017 - 2031
12.2.1. Antidepressants
12.2.2. Diuretics
12.2.3. Pain Relievers
12.2.4. Oral Contraceptives & Ovarian Suppression Agents
12.2.5. Others
12.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
12.3.1. Retail Pharmacies
12.3.2. E-commerce
12.3.3. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017 - 2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Premenstrual Syndrome Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Drug Type, 2017 - 2031
13.2.1. Antidepressants
13.2.2. Diuretics
13.2.3. Pain Relievers
13.2.4. Oral Contraceptives & Ovarian Suppression Agents
13.2.5. Others
13.3. Market Value Forecast, by Distribution Channel, 2017 - 2031
13.3.1. Retail Pharmacies
13.3.2. E-commerce
13.3.3. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017 - 2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis, by Company (2021)
14.3. Company Profiles
14.3.1. Allergan (AbbVie, Inc.)
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. Bayer AG
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Fresenius Kabi AG
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. Johnson & Johnson Services, Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Lilly
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. Mylan N.V. (Viatris, Inc.)
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Pfizer, Inc.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. Teva Pharmaceutical Industries Ltd
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Company Financials
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
List of Tables
Table 01: Global Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 02: Global Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 03: Global Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 04: North America Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 05: North America Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 06: North America Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: Europe Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 08: Europe Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 09: Europe Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Asia Pacific Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 11: Asia Pacific Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 12: Asia Pacific Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Latin America Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 14: Latin America Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 15: Latin America Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Middle East & Africa Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031
Table 17: Middle East & Africa Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 18: Middle East & Africa Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 02: Global Premenstrual Syndrome Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 03: Global Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Drug Type, 2022–2031
Figure 04: Global Premenstrual Syndrome Treatment Market Revenue (US$ Mn), by Antidepressants, 2017–2031
Figure 05: Global Premenstrual Syndrome Treatment Market Revenue (US$ Mn), by Diuretics, 2017–2031
Figure 06: Global Premenstrual Syndrome Treatment Market Revenue (US$ Mn), by Pain Relievers, 2017–2031
Figure 07: Global Premenstrual Syndrome Treatment Market Revenue (US$ Mn), by Oral Contraceptives & Ovarian Suppression Agents, 2017–2031
Figure 08: Global Premenstrual Syndrome Treatment Market Revenue (US$ Mn), by Others, 2017–2031
Figure 09: Global Premenstrual Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 10: Global Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Distribution Channel, 2022–2031
Figure 11: Global Premenstrual Syndrome Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031
Figure 12: Global Premenstrual Syndrome Treatment Market Revenue (US$ Mn), by E-commerce, 2017–2031
Figure 13: Global Premenstrual Syndrome Treatment Market Revenue (US$ Mn), by Other, 2017–2031
Figure 14: Global Premenstrual Syndrome Treatment Market Value Share Analysis, by Region, 2021 and 2031
Figure 15: Global Premenstrual Syndrome Treatment Market Attractiveness Analysis, by Region, 2021–2031
Figure 16: North America Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 17: North America Premenstrual Syndrome Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 18: North America Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Drug Type, 2022–2031
Figure 19: North America Premenstrual Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 20: North America Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Distribution Channel, 2022–2031
Figure 21: North America Premenstrual Syndrome Treatment Market Value Share Analysis, by Country, 2021 and 2031
Figure 22: North America Premenstrual Syndrome Treatment Market Attractiveness Analysis, by Country, 2022–2031
Figure 23: Europe Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 24: Europe Premenstrual Syndrome Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 25: Europe Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Drug Type, 2022–2031
Figure 26: Europe Premenstrual Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 27: Europe Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Distribution Channel, 2022–2031
Figure 28: Europe Premenstrual Syndrome Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 29: Europe Premenstrual Syndrome Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 30: Asia Pacific Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 31: Asia Pacific Premenstrual Syndrome Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 32: Asia Pacific Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Drug Type, 2022–2031
Figure 33: Asia Pacific Premenstrual Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 34: Asia Pacific Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Distribution Channel, 2022–2031
Figure 35: Asia Pacific Premenstrual Syndrome Treatment Market Value Share Analysis, by Country, 2021 and 2031
Figure 36: Asia Pacific Premenstrual Syndrome Treatment Market Attractiveness Analysis, by Country, 2022–2031
Figure 37: Latin America Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 38: Latin America Premenstrual Syndrome Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 39: Latin America Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Drug Type, 2022–2031
Figure 40: Latin America Premenstrual Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 41: Latin America Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Distribution Channel, 2022–2031
Figure 42: Latin America Premenstrual Syndrome Treatment Market Value Share Analysis, by Country, 2021 and 2031
Figure 43: Latin America Premenstrual Syndrome Treatment Market Attractiveness Analysis, by Country, 2022–2031
Figure 44: Middle East & Africa Premenstrual Syndrome Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 45: Middle East & Africa Premenstrual Syndrome Treatment Market Value Share Analysis, by Drug Type, 2021 and 2031
Figure 46: Middle East & Africa Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Drug Type, 2022–2031
Figure 47: Middle East & Africa Premenstrual Syndrome Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 48: Middle East & Africa Premenstrual Syndrome Treatment Market Attractiveness Index Analysis, by Distribution Channel, 2022–2031
Figure 49: Middle East & Africa Premenstrual Syndrome Treatment Market Value Share Analysis, by Country, 2021 and 2031
Figure 50: Middle East & Africa Premenstrual Syndrome Treatment Market Attractiveness Analysis, by Country, 2022–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Premenstrual Syndrome Treatment Market
